B-Cell Non-Hodgkin Lymphoma Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Takeda, Astrazeneca, BayeR, Novartis, Kite Pharma, Spectrum Pharma, Teva Pharma, Janssen, Genetech, Merck, Abbvie

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on developing various B-Cell Non-Hodgkin Lymphoma therapies based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-Cell Non-Hodgkin Lymphoma Therapeutics Market.

The report provides a detailed description of the B-Cell Non-Hodgkin Lymphoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the B-Cell Non-Hodgkin Lymphoma Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

B-Cell Non-Hodgkin Lymphoma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing B-Cell Non-Hodgkin Lymphoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging B-Cell Non-Hodgkin Lymphoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the B-Cell Non-Hodgkin Lymphoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the B-Cell Non-Hodgkin Lymphoma Therapeutics Domain:
https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging B-Cell Non-Hodgkin Lymphoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the B-Cell Non-Hodgkin Lymphoma Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Latest Development in the B-Cell Non-Hodgkin Lymphoma Therapeutics Landscape
On April 26, 2023, Artiva Biotherapeutics, Inc., announced that a poster describing initial data from the Phase 1/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell being investigated in combination with rituximab for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

B-Cell Non-Hodgkin Lymphoma Therapeutics Landscape
The B-Cell Non-Hodgkin Lymphoma therapeutic market dynamcis are anticipated to change in the coming years, owing to the launch of emerging therapies. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with B-cell NHL.

B-Cell Non-Hodgkin Lymphoma Companies in the Therapeutics Market Include:
Takeda Pharma, Astrazeneca, Bayer AG, Novartis, Kite Pharma, Spectrum Pharma, Teva Pharma, Bristol Myers Squibb Company, Janssen Pharma, Genetech Inc., Merck & co., Sanofi, Abbvie, Kyowa Kirin co. Ltd., and many others.

Emerging and Marketed B-Cell Non-Hodgkin Lymphoma (NHL) Therapies Covered in the Report Include:
The report covers the B-Cell Non-Hodgkin Lymphoma (NHL) Therapies such as Lisocabtagene maraleucel (JCAR017, a product of Bristol-Myers Squibb), KTE-X19 (Gilead Sciences), Tafasitamab (MOR208, a product of MorphoSys AG), Tazemetostat (E7438, a product of Epizyme), Abexinostat (Xynomic Pharmaceuticals), Umbralisib (TG Therapeutics), Avelumab (Pfizer/Merck) and many more.

Get an in-depth Assessment of the Emerging Therapies and B-Cell Non-Hodgkin Lymphoma Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. B-Cell Non-Hodgkin Lymphoma Current Treatment Patterns
4. B-Cell Non-Hodgkin Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-Cell Non-Hodgkin Lymphoma Late-Stage Products (Phase-III)
7. B-Cell Non-Hodgkin Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-Cell Non-Hodgkin Lymphoma Discontinued Products
13. B-Cell Non-Hodgkin Lymphoma Product Profiles
14. B-Cell Non-Hodgkin Lymphoma Companies
15. B-Cell Non-Hodgkin Lymphoma Drugs
16. Dormant and Discontinued Products
17. B-Cell Non-Hodgkin Lymphoma Unmet Needs
18. B-Cell Non-Hodgkin Lymphoma Future Perspectives
19. B-Cell Non-Hodgkin Lymphoma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Chronic Idiopathic Constipation Market
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-market

Hay Fever Conjunctivitis Market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Chronic Focal Epilepsy Market
https://www.delveinsight.com/report-store/chronic-focal-epilepsy-market

Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market

Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market

Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market

Failed Back Surgery Syndrome Market
https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market

Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report

Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Nasolabial Fold Market
https://www.delveinsight.com/report-store/nasolabial-fold-market

Neuroleptic Malignant Syndrome Market
https://www.delveinsight.com/report-store/neuroleptic-malignant-syndrome-market

Pachyonychia Congenita Market
https://www.delveinsight.com/report-store/pachyonychia-congenita-market

Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

Reactive Airway Disease Market
https://www.delveinsight.com/report-store/reactive-airway-disease-market

Seborrhea Market
https://www.delveinsight.com/report-store/seborrhea-market

Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Synchronous Endometrial and Ovarian Cancer (SEOC) Market
https://www.delveinsight.com/report-store/synchronous-endometrial-and-ovarian-cancer-seoc-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Urinary Tract Infection Devices Market
https://www.delveinsight.com/report-store/urinary-tract-infection-devices-market

Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market

Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.